IgM and IgG antibodies to hepatitis E virus (HEV) detected by an enzyme immunoassay based on an HEV-specific artificial recombinant mosaic protein
- 1 September 1996
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 50 (1) , 50-58
- https://doi.org/10.1002/(sici)1096-9071(199609)50:1<50::aid-jmv10>3.0.co;2-1
Abstract
To develop an enzyme immunoassay (EIA) for IgM antibody to hepatitis E virus (HEV) (IgM anti-HEV) and IgG antibody to HEV (IgG anti-HEV), a synthetic gene encoding several liner immuno-dominant antigenic epitopes from HEV structural proteins was assembled as a chimeric recombinant mosaic protein (Mpr) with glutathione S-transferase and used as an immunodiagnostic target. In addition, a neutralization confirmation test was developed using individual synthetic peptides. Among 614 patients with acute hepatitis from 10 geographically distinct outbreaks, IgG anti-HEV was found in 546 (88.9%), with a range of 77–100% depending on the outbreak. Of 130 patients tested for IgM anti-HEV, 126 (96.9%) were positive. Among patients tested within 4 months of onset of jaundice, 37/37 (100%) were IgG anti-HEV positive. For patients from whom sera were collected 1–16 days after onset of jaundice, the geometric mean IgG titer (GMT) was 1:47,000; the GMT increased to 1:70,710 30–40 days after onset of jaundice and decreased to 1:1,778 3–4 months after the onset of jaundice. For patients tested 6–8 months after onset of jaundice, 11/12 (92%) were IgG anti-HEV positive, and the GMT was 1:2,908. IgM anti-HEV was detected in 43/43 (100%) sera collected 1–40 days after onset of jaundice, and the GMT for IgM anti-HEV was 1:10,000 at that time. For sera collected 3–4 and 6–12 months after onset of jaundice, 7/14 (50%) and 5/12 (40%) respectively, were IgM anti-HEV positive. In conclusion, an artificial mosaic protein composed of linear antigenic epitopes from open reading frame 2 (ORF2) and ORF3 of HEV has been successfully applied to the development of a sensitive and specific EIA for the detection of IgG and IgM anti-HEV activity. These assays were used for the verification of HEV infection in outbreak settings and for the diagnosis of HEV infection in sporadic cases.Keywords
This publication has 26 references indexed in Scilit:
- Epidemic Hepatitis E In Pakistan: Patterns Of Serologic Response And Evidence That Antibody To Hepatitis E Virus Protects Against DiseaseThe Journal of Infectious Diseases, 1994
- Serological studies of an enterically transmitted non‐A, non‐B hepatitis in SomaliaJournal of Medical Virology, 1993
- The sequence of hepatitis E virus isolated directly from a single source during an outbreak in ChinaVirus Research, 1993
- Mapping of linear B cell epitopes on open reading frames 2- and 3-encoded proteins of hepatitis E virus using synthetic peptidesFEMS Microbiology Letters, 1993
- Sequence and gene structure of the hepatitis E virus isolated from MyanmarVirus Genes, 1993
- Seroepidemiological survey of hepatitis E in Hong Kong by recombinant-based enzyme immunoassaysThe Lancet, 1992
- Serologic identification of hepatitis E virus infections in epidemic and endemic settingsJournal of Medical Virology, 1992
- Enzyme-linked immunosorbent assay for diagnosis of acute sporadic hepatitis E in Egyptian childrenThe Lancet, 1992
- Hepatitis E virus.BMJ, 1990
- Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferaseGene, 1988